CytoDyn, Inc.-2018

Date/Time

6/20/2018
11:30 AM - 1:00 PM

Location

The Racquet Club of Philadelphia

Description

CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection. The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has completed Phase 2 clinical trials with demonstrated antiviral activity in humans and is currently in Phase 3 development. PRO 140 blocks the HIV co-receptor CCR5 on T cells, which prevents viral entry. COMPANY REPS: CEO: Nader Pourhassan CFO: Michael Mulholland And Tony Schor